Open Access
ARTICLE
Inhibition of MMP-2 Expression Enhances the Antitumor Effect of Sorafenib in Hepatocellular Carcinoma by Suppressing the PI3K/AKT/mTOR Pathway
Wenliang Tan*†1, Sicong Zhu*†1, Jun Cao*†, Lei Zhang*†, Wenda Li*†, Kairui Liu*†, Jinyi Zhong†,
Changzhen Shang*†, Yajin Chen*†
* Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Medical Research Center,
Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, P.R. China
† Department of Hepatobiliary Surgery, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, P.R. China
1
These authors provided equal contribution to this work.
Oncology Research 2017, 25(9), 1543-1553. https://doi.org/10.3727/096504017X14886444100783
Abstract
Sorafenib has been globally approved as the standard treatment for patients with advanced hepatocellular carcinoma (HCC). However, the response rate of HCC patients to sorafenib is limited because of tumor recurrence
and metastasis. Therefore, seeking combined therapeutic strategies with sorafenib is necessary to improve
the antitumor efficiency. Here we demonstrated that expression of MMP-2 is positively correlated with the
migration ability of HCC cells. Cells with a higher MMP-2 expression (SK-HEP-1 cells) were less sensitive
to sorafenib than those with lower MMP-2 expression (HepG2 cells). Cotreatment of cells with SB-3CT and
sorafenib more strongly inhibited migration ability than with sorafenib treatment alone in both HCC cells with
high and low expression of MMP-2. In vivo cell metastasis experiments confirmed the synergistic effects of
sorafenib and SB-3CT in reducing lung metastasis of SK-HEP-1 cells. Mechanistically, we showed that the
synergistic antitumor effect may be attributed to inhibition of the PI3K/AKT/mTOR signaling pathway, but not
the RAF/MEK/ERK signaling pathway. With these results taken together, the current study demonstrates that
inhibiting MMP-2 expression can enhance the antitumor effect of sorafenib in HCC cells with a high MMP-2
expression, which may provide a novel strategy to improve therapeutic efficiency in HCC.
Keywords
Cite This Article
APA Style
Tan, W., Zhu, S., Cao, J., Zhang, L., Li, W. et al. (2017). Inhibition of MMP-2 expression enhances the antitumor effect of sorafenib in hepatocellular carcinoma by suppressing the pi3k/akt/mtor pathway. Oncology Research, 25(9), 1543-1553. https://doi.org/10.3727/096504017X14886444100783
Vancouver Style
Tan W, Zhu S, Cao J, Zhang L, Li W, Liu K, et al. Inhibition of MMP-2 expression enhances the antitumor effect of sorafenib in hepatocellular carcinoma by suppressing the pi3k/akt/mtor pathway. Oncol Res. 2017;25(9):1543-1553 https://doi.org/10.3727/096504017X14886444100783
IEEE Style
W. Tan et al., "Inhibition of MMP-2 Expression Enhances the Antitumor Effect of Sorafenib in Hepatocellular Carcinoma by Suppressing the PI3K/AKT/mTOR Pathway," Oncol. Res., vol. 25, no. 9, pp. 1543-1553. 2017. https://doi.org/10.3727/096504017X14886444100783